✅ This trial is currently recruiting volunteers
If you think you might be eligible, speak to your GP or specialist about this trial before applying.
Status
Recruiting
Phase
N/A
Participants
ALL
Age Range
18 Years+
About This Trial
This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis factor-alpha inhibitor (e.g., adalimumab or etanercept) at NHS hospitals in the United Kingdom. Information from patients' medical records will be collected, and patients will complete surveys about their experiences with their treatment. The study will look at treatment effectiveness from both healthcare professionals' and patients' points of view.
Who Can Join?
Inclusion Criteria: * Participant has a clinical diagnosis of axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA). * Participant has been prescribed advanced therapy within one month prior to enrolment in the study, to treat their axSpA or PsA. * Participant is aged 18 years or older at enrolment. Exclusion Criteria: -Participation in a clinical trial at enrolment.
⚠ Always speak to your doctor before applying to any clinical trial.
More Cancer Trials
Recruiting
The PROFILE Study: Germline Genetic Profiling: Correlation With Targeted Prostate Cancer Screening and Treatment
Recruiting PHASE3A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and…
Recruiting PHASE3MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia…